15.145  0.015 (0.1%)		05-17 15:59
Open: 15.15 High: 15.165 Volume: 922,504		Pre. Close: 15.13 Low: 15.14 Market Cap: 224(M)

Short term
Mid term
Targets	6-month :	17.71	1-year :	20.68
Resists	First :	15.16	Second :	17.71
Pivot price	15.09
Supports	First :	14.86	Second :	14.68
MAs	MA(5) :	15.13	MA(20) :	15.03
	MA(100) :	14.37	MA(250) :	13.17
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	82.2	D(3) :	86.4
RSI	RSI(14): 76.5
52-week	High :	15.89	Low :	11.52

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MACK ] has closed below upper band by 31.7%. Bollinger Bands are 63.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	15.14 - 15.22	15.22 - 15.28
Low:	14.95 - 15.04	15.04 - 15.11
Close:	15 - 15.13	15.13 - 15.25

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Fri, 10 May 2024
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock - Business Wire

Thu, 09 May 2024
EX-99.1 - SEC.gov

Tue, 30 Apr 2024
Merrimack Pharmaceuticals plans NASDAQ delisting and liquidation - Investing.com

Tue, 13 Feb 2024
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDA - Business Wire

Mon, 27 Jul 2020
Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Fortress Investment Group, Fulcrum Asset Management, Guess?, Inc. (GES), Merrimack Pharmaceuticals Inc (MACK), and More - Insider Monkey

Sat, 14 Oct 2017
Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	15 (M)
Shares Float	10 (M)
Held by Insiders	1.1 (%)
Held by Institutions	62.9 (%)
Shares Short	842 (K)
Shares Short P.Month	723 (K)

EPS	-0.1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	15.25
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-1.1 %
Return on Equity (ttm)	-1.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-2 (M)
Levered Free Cash Flow	21 (M)

PE Ratio	-168.12
PEG Ratio	0
Price to Book value	0.99
Price to Sales	0
Price to Cash Flow	-90.24

Dividend	15.1
Forward Dividend	0
Dividend Yield	99.8%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.